OBJECTIVE: Macrophage migration inhibitory factor (MIF) facilitates multiple aspects of inflammatory arthritis, the pathogenesis of which has been significantly linked to the activity of neutrophils. The effects of MIF on neutrophil recruitment are unknown. This study was undertaken to investigate the contribution of MIF to the regulation of neutrophil chemotactic responses. METHODS: K/BxN serum-transfer arthritis was induced in wild-type (WT), MIF(-/-) , and monocyte chemotactic protein 1 (MCP-1; CCL2)-deficient mice as well as in WT mice treated with monoclonal antibodies to cytokine-induced neutrophil chemoattractant (anti-KC). Leukocyte trafficking in vivo was examined using intravital microscopy, and neutrophil function in vitro was examined using migration chambers and assessment of MAP kinase activation. RESULTS: K/BxN serum-transfer arthritis was markedly attenuated in MIF(-/-) mice, with reductions in the clinical and histologic severity of arthritis and the synovial expression of KC and interleukin-1. Arthritis was also reduced by anti-KC antibody treatment, but not in MCP-1-deficient mice. In vivo, neutrophil recruitment responses to KC were reduced in MIF(-/-) mice. Similarly, MIF(-/-) mouse neutrophils exhibited reduced chemotactic responses to KC in vitro, despite displaying unaltered chemokine receptor expression. Reduced chemotactic responses of MIF(-/-) mouse neutrophils were associated with reduced phosphorylation of p38 and ERK MAP kinases. CONCLUSION: These findings suggest that MIF promotes neutrophil trafficking in inflammatory arthritis via facilitation of chemokine-induced migratory responses and MAP kinase activation. Therapeutic MIF inhibition could limit synovial neutrophil recruitment.
OBJECTIVE:Macrophage migration inhibitory factor (MIF) facilitates multiple aspects of inflammatory arthritis, the pathogenesis of which has been significantly linked to the activity of neutrophils. The effects of MIF on neutrophil recruitment are unknown. This study was undertaken to investigate the contribution of MIF to the regulation of neutrophil chemotactic responses. METHODS: K/BxN serum-transfer arthritis was induced in wild-type (WT), MIF(-/-) , and monocyte chemotactic protein 1 (MCP-1; CCL2)-deficient mice as well as in WT mice treated with monoclonal antibodies to cytokine-induced neutrophil chemoattractant (anti-KC). Leukocyte trafficking in vivo was examined using intravital microscopy, and neutrophil function in vitro was examined using migration chambers and assessment of MAP kinase activation. RESULTS: K/BxN serum-transfer arthritis was markedly attenuated in MIF(-/-) mice, with reductions in the clinical and histologic severity of arthritis and the synovial expression of KC and interleukin-1. Arthritis was also reduced by anti-KC antibody treatment, but not in MCP-1-deficientmice. In vivo, neutrophil recruitment responses to KC were reduced in MIF(-/-) mice. Similarly, MIF(-/-) mouse neutrophils exhibited reduced chemotactic responses to KC in vitro, despite displaying unaltered chemokine receptor expression. Reduced chemotactic responses of MIF(-/-) mouse neutrophils were associated with reduced phosphorylation of p38 and ERK MAP kinases. CONCLUSION: These findings suggest that MIF promotes neutrophil trafficking in inflammatory arthritis via facilitation of chemokine-induced migratory responses and MAP kinase activation. Therapeutic MIF inhibition could limit synovial neutrophil recruitment.
Authors: M Leech; C Metz; P Hall; P Hutchinson; K Gianis; M Smith; H Weedon; S R Holdsworth; R Bucala; E F Morand Journal: Arthritis Rheum Date: 1999-08
Authors: T Ohkawara; K Miyashita; J Nishihira; K Mitsuyama; H Takeda; M Kato; N Kondo; Y Yamasaki; M Sata; T Yoshiki; T Sugiyama; M Asaka Journal: Clin Exp Immunol Date: 2005-05 Impact factor: 4.330
Authors: H Makita; M Nishimura; K Miyamoto; T Nakano; Y Tanino; J Hirokawa; J Nishihira; Y Kawakami Journal: Am J Respir Crit Care Med Date: 1998-08 Impact factor: 21.405
Authors: Antoine G Sreih; Rana Ezzedine; Lin Leng; Juan Fan; Jie Yao; Duncan Reid; Marta Piecychna; Simon Carette; David Cuthbertson; Paul Dellaripa; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Alfred Mahr; Carol A McAlear; Kathleen Maksimowicz-Mckinnon; Paul A Monach; Philip Seo; Ulrich Specks; E William St Clair; John H Stone; Steven R Ytterberg; Jeffrey Edberg; Peter A Merkel; Richard Bucala Journal: Arthritis Rheumatol Date: 2018-10-22 Impact factor: 10.995
Authors: Ran Gu; Leilani L Santos; Devi Ngo; HuaPeng Fan; Preetinder P Singh; Gunter Fingerle-Rowson; Richard Bucala; Jiake Xu; Julian M W Quinn; Eric F Morand Journal: Cytokine Date: 2015-01-31 Impact factor: 3.861
Authors: Konstantin Stark; Annekathrin Eckart; Selgai Haidari; Anca Tirniceriu; Michael Lorenz; Marie-Luise von Brühl; Florian Gärtner; Alexander Georg Khandoga; Kyle R Legate; Robert Pless; Ingrid Hepper; Kirsten Lauber; Barbara Walzog; Steffen Massberg Journal: Nat Immunol Date: 2012-11-25 Impact factor: 25.606
Authors: David A White; Yidan Su; Peter Kanellakis; Helen Kiriazis; Eric F Morand; Richard Bucala; Anthony M Dart; Xiao-Ming Gao; Xiao-Jun Du Journal: J Mol Cell Cardiol Date: 2014-02-05 Impact factor: 5.000
Authors: Rafael Sanguinetti Czepielewski; Bárbara Nery Porto; Lucas Bortolotto Rizzo; Rafael Roesler; Ana Lúcia Abujamra; Larissa Garcia Pinto; Gilberto Schwartsmann; Fernando de Queiroz Cunha; Cristina Bonorino Journal: Proc Natl Acad Sci U S A Date: 2011-12-27 Impact factor: 11.205
Authors: Jean-Claude A Marshall; Joshua W Collins; Joji Nakayama; Christine E Horak; David J Liewehr; Seth M Steinberg; Mary Albaugh; Fernando Vidal-Vanaclocha; Diane Palmieri; Maryse Barbier; Maximilien Murone; Patricia S Steeg Journal: J Natl Cancer Inst Date: 2012-08-21 Impact factor: 13.506